Deals and Data

Deals and Data

Sanofi partners with SK Chemical Co to develop and market vaccine against pneumococcal infection. (Reuters, 03/19/14)

Astellas and Medivation seek FDA approval for prostate cancer treatment for men with metastatic castration-resistant prostate cancer who have no received chemo. (Zacks, 03/19/14)

UC San Diego develops computer system that detects whether pain is real; could help warn drivers when they are dozing off behind the wheel. (U-T San Diego, 03/20/14)

Sanford-Burnham Medical Research Institute study shows inhibiting a single microRNA could stop progression of heart failure in mouse model while boosting the animals' cardiac function and survival. (GenomeWeb, 03/20/14)

NIH awards The Scripps Research Institute $28 million to develop an antibody cocktail to repel the deadly Ebola virus. (U-T San Diego, 03/20/14)

FDA approves Celgene’s drug to treat psoriatic arthritis; skin disease psoriasis that causes joint pain, stiffness and swelling. (Reuters, 03/21/14)

Salk Institute study shows a gene that guards against cancer also plays important role in brain development. (U-T San Diego, 03/22/14)

Novartis’ secukinumab shows high efficacy in patients suffering from moderate-to-severe plaque psoriasis. (Reuters, 03/22/14)

Illumina named world’s smartest company on MIT Technology Review’s annual list. (U-T San Diego, 03/23/14)

DermTech completes CLIA licensure of San Diego lab facility; validates testing of its proprietary Pigmented Lesion Assay. (GenomeWeb, 03/24/14)

Monsanto partners with MIT researchers to form Preceres LLC; new company will focus on developing technologies to create new biological products for pest, virus and weed control. (St. Louis Today, 03/24/14)

Pfizer’s Xalkori delays progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease. (Reuters, 03/25/14)

Halozyme Therapeutics' HTI-501 improves cellulite appearnce; recombinat human enzyme breaks down collagen fibers beneath skin at injection site. (U-T San Diego, 03/25/14)

UCSD study shows autism begins in pregnancy with subtle disruption of the brain’s cortex; mechanism of abnormal gene activity explains how disruption causes autism. (U-T San Diego, 03/26/14)

Genentech and Xenon Pharmaceuticals collaborate to find and validate new therapeutic targets and mechanisms to treat pain. (GEN News, 03/26/14)

GlaxoSmithKline receives EU marketing approval for its once-weekly, type-2 diabetes drug. (Reuters, 03/26/14)

FDA clears Quidel’s AmpliVue HSV 1+2 Assay for differentiating and detecting herpes simplex viruses 1 and 2. (GenomeWeb, 03/28/14)

Amgen Inc's evolocumab lowers bad LDL cholesterol by 55% to 66% compared with a placebo in late-stage clinical trials. (Reuters, 03/29/14)

Novartis to end late-stage trial of chronic heart failure drug early due to strong results; patients receiving drug live longer. (Reuters, 03/31/14)

Celgene and Forma Therapeutics collaborate to identify potential new drugs which can be licensed by Celgene. (BioFlash, 04/01/14)

« Return to Table of Contents